Table 2.
Univariate analysis for prediction of adverse clinical events
| Variable | Hazard ratio | 95% confidence interval | P value |
|---|---|---|---|
| Age (per 1 year) | 1.013 | 0.965 – 1.062 | 0.604 |
| Male sex | 1.547 | 0.420 – 5.696 | 0.512 |
| BMI (per 1 kg/m2) | 1.250 | 0.966 – 1.618 | 0.090 |
| WHO functional class 4 | 0.653 | 0.084 – 5.102 | 0.685 |
| High-risk profile | 4.745 | 1.362 – 16.524 | 0.014 |
| Hypertension | 1.869 | 0.606 – 5.767 | 0.276 |
| Diabetes mellitus | 0.495 | 0.064 – 3.843 | 0.502 |
| LVEF (per 1%) | 1.001 | 0.872 – 1.148 | 0.994 |
| RVSP (per 1 mmHg) | 1.012 | 0.994 – 1.031 | 0.179 |
| TAPSE (per 1 mm) | 0.943 | 0.819 – 1.085 | 0.410 |
| Tricuspid annular S’ velocity (per 1 cm/s) | 0.877 | 0.683 – 1.126 | 0.303 |
| RA area (per 1 cm2) | 1.030 | 0.992 – 1.069 | 0.120 |
| Mean PA pressure (per 1 mmHg) | 1.020 | 0.984 – 1.057 | 0.276 |
| PCWP (per 1 mmHg) | 1.025 | 0.904 – 1.163 | 0.696 |
| PVR (per 1 WU) | 1.013 | 0.931 – 1.103 | 0.761 |
| CI (per 1 l/min/m2) | 1.000 | 0.999 – 1.001 | 0.790 |
| FVC (per 1 L) | 0.641 | 0.236 – 1.745 | 0.384 |
| FEV1 (per 1 L) | 0.410 | 0.120 – 1.396 | 0.154 |
| DLCO (per 1 mL/min/mmHg) | 0.948 | 0.850 – 1.058 | 0.340 |
| Total distance (per 1 m) | 0.992 | 0.986 – 0.998 | 0.009 |
| VO2 peak (per 1 mL/(kg⋅min)) | 0.861 | 0.712 – 1.042 | 0.125 |
| HR peak (per 1/min) | 0.991 | 0.968 – 1.015 | 0.465 |
| VE/VO2 slope (per 1 mL/min/W) | 1.039 | 0.992 – 1.090 | 0.108 |
| EID | 6.099 | 1.783 – 20.869 | 0.004 |
BMI body mass index, CI cardiac index, DLCO diffusing capacity of the lung for carbon monoxide, EID exercise induced desaturation, FEV1 forced expiratory volume at 1 s, FVC forced vital capacity, HR heart rate, LVEF left ventricular ejection fraction, PA pulmonary artery, PCWP pulmonary capillary wedge pressure, PVR pulmonary vascular resistance, RA right atrium, RVSP right ventricular systolic pressure, TAPSE tricuspid annular plane systolic excursion, VE ventilatory equivalent of O2, VO2 maximal oxygen consumption, WHO World Health Organization